These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 17325887

  • 1. A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase.
    Quintás-Cardama A, Kantarjian H, Garcia-Manero G, O'Brien S, Faderl S, Ravandi F, Giles F, Thomas D, Wierda W, Cortes J.
    Leuk Lymphoma; 2007 Feb; 48(2):283-9. PubMed ID: 17325887
    [Abstract] [Full Text] [Related]

  • 2. Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance.
    Verma D, Kantarjian HM, Jones D, Luthra R, Borthakur G, Verstovsek S, Rios MB, Cortes J.
    Blood; 2009 Sep 10; 114(11):2232-5. PubMed ID: 19531657
    [Abstract] [Full Text] [Related]

  • 3. Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis.
    Fruehauf S, Topaly J, Buss EC, Fischer T, Ottmann OG, Emmerich B, Müller MC, Schuld P, Balleisen L, Hehlmann R, Ho AD, Hochhaus A.
    Cancer; 2007 Apr 15; 109(8):1543-9. PubMed ID: 17340589
    [Abstract] [Full Text] [Related]

  • 4. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
    Cohen MH, Johnson JR, Pazdur R.
    Clin Cancer Res; 2005 Jan 01; 11(1):12-9. PubMed ID: 15671523
    [Abstract] [Full Text] [Related]

  • 5. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
    Zhang GC, Zheng D, Li QH, Li XH, Cai CC, Luo SK, Li J, Peng AH, Tong XZ, Tan EX, Hong WD.
    Ai Zheng; 2004 Dec 01; 23(12):1696-9. PubMed ID: 15601563
    [Abstract] [Full Text] [Related]

  • 6. The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study).
    Deau B, Nicolini FE, Guilhot J, Huguet F, Guerci A, Legros L, Pautas C, Berthou C, Guyotat D, Cony-Makhoul P, Gardembas M, Michallet M, Hayette S, Cayuela JM, Weiss IR, Réa D, Castaigne S, Mahon FX, Guilhot F, Rousselot P.
    Leuk Res; 2011 Jun 01; 35(6):777-82. PubMed ID: 21145590
    [Abstract] [Full Text] [Related]

  • 7. Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase.
    Gardembas M, Rousselot P, Tulliez M, Vigier M, Buzyn A, Rigal-Huguet F, Legros L, Michallet M, Berthou C, Cheron N, Maloisel F, Mahon FX, Facon T, Berthaud P, Guilhot J, Guilhot F, CML French Group.
    Blood; 2003 Dec 15; 102(13):4298-305. PubMed ID: 12933584
    [Abstract] [Full Text] [Related]

  • 8. Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib.
    Cortes J, Jabbour E, Daley GQ, O'Brien S, Verstovsek S, Ferrajoli A, Koller C, Zhu Y, Statkevich P, Kantarjian H.
    Cancer; 2007 Sep 15; 110(6):1295-302. PubMed ID: 17623836
    [Abstract] [Full Text] [Related]

  • 9. HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia.
    Strati P, Kantarjian H, Thomas D, O'Brien S, Konoplev S, Jorgensen JL, Luthra R, Abruzzo L, Jabbour E, Quintas-Cardama A, Borthakur G, Faderl S, Ravandi F, Cortes J.
    Cancer; 2014 Feb 01; 120(3):373-80. PubMed ID: 24151050
    [Abstract] [Full Text] [Related]

  • 10. High-dose cytosine arabinoside and idarubicin treatment of chronic myeloid leukemia in myeloid blast crisis.
    Barone S, Baer MR, Sait SN, Lawrence D, Block AW, Wetzler M.
    Am J Hematol; 2001 Jun 01; 67(2):119-24. PubMed ID: 11343384
    [Abstract] [Full Text] [Related]

  • 11. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.
    Palandri F, Castagnetti F, Testoni N, Luatti S, Marzocchi G, Bassi S, Breccia M, Alimena G, Pungolino E, Rege-Cambrin G, Varaldo R, Miglino M, Specchia G, Zuffa E, Ferrara F, Bocchia M, Saglio G, Pane F, Alberti D, Martinelli G, Baccarani M, Rosti G, GIMEMA Working Party on Chronic Myeloid Leukemia.
    Haematologica; 2008 Dec 01; 93(12):1792-6. PubMed ID: 18838477
    [Abstract] [Full Text] [Related]

  • 12. Idarubicin and intermediate-dose cytarabine for myeloid blast crisis of chronic myelogenous leukemia--results of a phase-II trial.
    Schneller F, Schuler M, Schumacher K, Thaler J, Peschel C, Huber C, Aulitzky W.
    Ann Hematol; 1998 Nov 01; 77(5):225-9. PubMed ID: 9858148
    [Abstract] [Full Text] [Related]

  • 13. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
    O'Brien S, Giles F, Talpaz M, Cortes J, Rios MB, Shan J, Thomas D, Andreeff M, Kornblau S, Faderl S, Garcia-Manero G, White K, Mallard S, Freireich E, Kantarjian HM.
    Cancer; 2003 Sep 01; 98(5):888-93. PubMed ID: 12942553
    [Abstract] [Full Text] [Related]

  • 14. [Combination of imatinib and anagrelide in treatment of chronic myeloid leukemia in blastic phase].
    Voglová J, Maisnar V, Beránek M, Chrobák L.
    Vnitr Lek; 2006 Sep 01; 52(9):819-22. PubMed ID: 17091608
    [Abstract] [Full Text] [Related]

  • 15. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
    Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA, IRIS Investigators.
    N Engl J Med; 2006 Dec 07; 355(23):2408-17. PubMed ID: 17151364
    [Abstract] [Full Text] [Related]

  • 16. Successful treatment of lymphoid blastic crisis in chronic myelogenous leukemia with the additional bcr/abl transcript using imatinib-combined chemotherapy and high-dose chemotherapy with allogeneic bone marrow stem cell transplantation.
    Kawano N, Okuda S, Yoshida S, Kugimiya H, Ito M, Horikawa N, Chosa N, Hisakata T, Fukudome T, Sakurai R, Yamashita K, Ueda A, Kanda Y.
    Int J Hematol; 2011 Dec 07; 94(6):561-6. PubMed ID: 22057509
    [Abstract] [Full Text] [Related]

  • 17. Early imatinib-mesylate-induced hepatotoxicity in chronic myelogenous leukaemia.
    Kong JH, Yoo SH, Lee KE, Nam SH, Kwon JM, Lee SM, Chang HJ, Choi MY, Cho MS, Mun YC, Nam E, Lee SN, Seong CM.
    Acta Haematol; 2007 Dec 07; 118(4):205-8. PubMed ID: 18030002
    [Abstract] [Full Text] [Related]

  • 18. Imatinib mesylate as first-line therapy in patients with chronic myeloid leukemia in accelerated phase and blast phase: a retrospective analysis.
    Thota NK, Gundeti S, Linga VG, Coca P, Tara RP, Raghunadharao.
    Indian J Cancer; 2014 Dec 07; 51(1):5-9. PubMed ID: 24947087
    [Abstract] [Full Text] [Related]

  • 19. High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial.
    Guilhot F, Druker B, Larson RA, Gathmann I, So C, Waltzman R, O'Brien SG.
    Haematologica; 2009 Dec 07; 94(12):1669-75. PubMed ID: 19648168
    [Abstract] [Full Text] [Related]

  • 20. Imatinib activity in vitro in tumor cells from patients with chronic myeloid leukemia in chronic phase and blast crisis.
    Olsson-Strömberg U, Aleskog A, Björnberg A, Höglund M, Simonsson B, Bengtsson M, Barbany G, Larsson R, Lindhagen E.
    Anticancer Drugs; 2006 Jul 07; 17(6):631-9. PubMed ID: 16917208
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.